Sanwa and Kowa's DPP-4 licensing deal goes global
This article was originally published in Scrip
Sanwa Kagaku Kenkyushohas granted fellow Japanese firm Kowaexclusive development and marketing rights to its antidiabetic DPP-4 inhibitor, SK-0403, in all markets worldwide excluding South Korea, China and Taiwan. The agreement extends an August co-development and co-commercialisation alliance for Japan, where SK-0403 is in Phase II trials. Sanwa will receive undisclosed upfront, milestone and royalty payments. Kowa recently extended its US marketing capability through the acquisition of ProEthic Pharmaceuticals in August (Scrip Online, August 5th, 2008).
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.